CombinatoRx (CRXX) Reports Phase 2b Trials of Synavive Did Not Demonstrate Statistical Significance
Tweet Send to a Friend
CombinatoRx, Incorporated (NASDAQ: CRXX), today announced preliminary top-line results from COMET-1, the Company's Phase 2b clinical trial designed to evaluate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
